China Antisense And Rnai Therapeutics Market Size & Outlook

The antisense and rnai therapeutics market in China is expected to reach a projected revenue of US$ 272.9 million by 2030. A compound annual growth rate of 22.9% is expected of China antisense and rnai therapeutics market from 2025 to 2030.
Revenue, 2024 (US$M)
$81.2
Forecast, 2030 (US$M)
$272.9
CAGR, 2025 - 2030
22.9%
Report Coverage
China

China antisense and rnai therapeutics market, 2018-2030 (US$M)

China

Related Markets

China antisense and rnai therapeutics market highlights

  • The China antisense and rnai therapeutics market generated a revenue of USD 68.2 million in 2023 and is expected to reach USD 272.9 million by 2030.
  • The China market is expected to grow at a CAGR of 21.9% from 2024 to 2030.
  • In terms of segment, antisense rna was the largest revenue generating technology in 2023.
  • Antisense RNA is the most lucrative technology segment registering the fastest growth during the forecast period.


Antisense and rnai therapeutics market data book summary

Market revenue in 2023USD 68.2 million
Market revenue in 2030USD 272.9 million
Growth rate21.9% (CAGR from 2023 to 2030)
Largest segmentAntisense rna
Fastest growing segmentAntisense RNA
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationAntisense RNA
Key market players worldwideGSK PLC, Sanofi SA, Alnylam Pharmaceuticals Inc, Arbutus Biopharma Corp, Benitec Biopharma Inc, Silence Therapeutics PLC, Ionis Pharmaceuticals Inc, Sarepta Therapeutics Inc, Percheron Therapeutics Ltd


Other key industry trends

  • In terms of revenue, China accounted for 1.6% of the global antisense and rnai therapeutics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, Japan antisense and rnai therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 272.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Antisense And RNAi Therapeutics Market Companies

Name Profile # Employees HQ Website

China antisense and rnai therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antisense and rnai therapeutics market will help companies and investors design strategic landscapes.


Antisense rna was the largest segment with a revenue share of 100% in 2024. Horizon Databook has segmented the China antisense and rnai therapeutics market based on antisense rna covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to China antisense and rnai therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China antisense and rnai therapeutics market databook

  • Our clientele includes a mix of antisense and rnai therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China antisense and rnai therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into China antisense and rnai therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China antisense and rnai therapeutics market size, by technology, 2018-2030 (US$M)

China Antisense And RNAi Therapeutics Market Outlook Share, 2024 & 2030 (US$M)

China antisense and rnai therapeutics market size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more